The full approval for Medicare reimbursement of Vivos Therapeutics' CARE oral medical devices is a significant milestone. It not only enhances the product's accessibility to a broader audience of Medicare beneficiaries but also has the potential to significantly increase the company's revenues. Given the size of the Medicare market and the prevalence of sleep-related breathing disorders, this approval could lead to increased demand for the CARE devices, positively impacting VVOS's stock price in the short term.